This site is intended only for healthcare professionals resident in the Republic of Ireland

Search

Menu

Close

Sign in or registerLog out Our medicinesTherapy areasExplore contentExplore contentMaterialsVideosPodcastsLet’s connectLet's connectContact usSign up
PortfolioSupport & ResourcesSidekick Digital Care AppPopit: A Smart Medication ReminderMaterialsVideosPodcasts
PortfolioXeljanz is indicated for the treatment of:1
  • Ulcerative colitis
 Access Prescribing Information LoadingInflectra is indicated for the treatment of:2
  • Adult Crohn’s disease
  • Paediatric Crohn’s disease
  • Ulcerative colitis
  • Paediatric ulcerative colitis
 Access Prescribing Information Loading
Click here to access XELJANZ Prescribing Information
Click here to access INFLECTRA Prescribing Information
References:XELJANZ Summary of Product CharacteristicsINFLECTRA Summary of Product Characteristics
Support & Resources

Learn more about resources available to support you and your patients.

 Find out more Loading

Legal Category: S1A
Further information is available upon request

PP-UNP-IRL-0354 January 2023

Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)
 

Adverse events should also be reported to Pfizer Medical Information on 1800 633 363

PfizerPro AccountPfizerPro Account

Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.

Sign in or RegisterRegisterAccountLog out

This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie

 

This website is brought to you by Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, Ireland. Registered in the Republic of Ireland No. 127002.

 

Copyright © 2023 Pfizer Limited. All rights reserved.

PP-UNP-IRL-0176. January 2023
You are now leaving PfizerPro
You are now leaving PfizerPro Ireland. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer. Pfizer accepts no responsibility for the content or services of the linked site.
For Healthcare Professionals in the Republic of Ireland *

The information contained on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland.

I confirm that I am a healthcare professional resident in the Republic of Ireland.*

I accept and agree to the terms of use.*

If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland.

PP-UNP-IRL-0176. January 2023

Yes No